The first second-generation adenosine drug enters the US market
Open Access
- 20 June 2008
- journal article
- research article
- Published by Springer Nature in Purinergic Signalling
- Vol. 4 (4) , 407-408
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humansJournal of Nuclear Cardiology, 2007
- 1170-142 Differential vasodilatory effects of CVT-3146, an A2Aadenosine receptor agonist in various vascular beds in anesthetized dogsJACC, 2004
- Selective A2A Adenosine Receptor Agonist as a Coronary Vasodilator in Conscious Dogs: Potential for Use in Myocardial Perfusion ImagingJournal of Cardiovascular Pharmacology, 2003
- A2A-Adenosine Receptor Reserve for Coronary VasodilationCirculation, 1998
- Pharmacological stress with adenosine for myocardial perfusion imagingSeminars in Nuclear Medicine, 1991